Methods of treating SARS Cov-2 virus with protocatechuic acid
View Patent ↗The present disclosure provides methods for killing the SARS CoV-2 virus in mammals and treating the Coronavirus Disease-19 (Covid-19) in mammals including humans using compositions including protocatechuic acid. The present disclosure provides methods and pharmaceutical and nutraceutical compositions that reduce or substantially eliminate the SARS CoV-2 virus in mammals. In one embodiment, a method of treating a mammal with Covid-19 is provided comprising administering protocatechuic acid to a mammal in need of such treatment a therapeutically effective amount of a protocatechuic acid composition.
1. A method of treating Covid-19 in a mammal comprising: administering to the mammal in need thereof a composition comprising protocatechuic acid.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the protocatechuic acid comprises protocatechuic acid crystals.
4. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier.
5. The method of claim 4 , wherein the pharmaceutically acceptable carrier is a biodegradable microsphere or a slow release bioabsorbable material.
6. The method of claim 4 , wherein the pharmaceutically acceptable carrier comprises D,L lactide/glycolide.
7. The method of claim 4 , wherein the administering is via topical, oral, buccal, injection, intravenous, peritoneal, inhalant, subcutaneous, sublingual, and/or transdermal administration.
8. The method of claim 1 , wherein the administering to the mammal is oral administration.
9. The method of claim 8 , wherein the oral administration dosage of protocatechuic acid is a minimum of 500 to about 1000 milligrams per day.
10. The method of claim 1 , wherein the administering to the mammal is through intravenous administration.
11. The method of claim 10 , wherein the administration includes 50 mg/kg of protocatechuic acid every 6 hours for 4 days.
12. The method of claim 1 , wherein the administering to the mammal is through intraperitoneal administration.
13. The method of claim 1 , wherein the administration to the mammal comprises coating of skin, oral cavity, nares, nasopharynx, and/or pulmonary tree with the composition comprising protocatechuic acid.
14. The method of claim 1 , wherein the administering to mammal is through a liquid spray, aerosol spray, and/or fog.
15. The method of claim 14 , wherein the composition further comprises a liquid vehicle and a stabilizer.
16. The method of claim 15 , wherein the liquid vehicle is water.
17. The method of claim 15 , wherein the stabilizer is an essential oil.
18. The method of claim 14 , wherein the administration is to the skin.
19. The method of claim 14 , wherein the administration is to the lungs.
20. The method of claim 14 , wherein the administration is to the nasal cavity.